Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques F Meis

Showing results (61-70 of 430) with videos related to

Pageof 43
Sort By:
Mycoses|December 11, 2019
Genotypic diversity in clinical and environmental isolates of Cryptococcus neoformans from India using multilocus microsatellite and multilocus sequence typingAnupam Prakash, Gandhi Sundar, Brijesh Sharma, et al.
Mycoses|February 11, 2021
COVID-19-associated pulmonary aspergillosis: a prospective single-center dual case seriesEelco F J Meijer, Anton S M Dofferhoff, Oscar Hoiting, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 10, 2021
Antifungal activity of nitroxoline against Candida auris isolatesFrieder Fuchs, Herbert Hof, Sandra Hofmann, et al.
Emerging Infectious Diseases|August 23, 2014
Passive surveillance for azole-resistant Aspergillus fumigatus, United States, 2011-2013Cau D Pham, Errol Reiss, Ferry Hagen, et al.
Mycoses|March 11, 2015
In vitro susceptibility patterns of clinically important Trichophyton and Epidermophyton species against nine antifungal drugsHamid Badali, Rasoul Mohammadi, Olga Mashedi, et al.
Antimicrobial Agents and Chemotherapy|April 24, 2016
Are the TR46/Y121F/T289A Mutations in Azole-Resistant Aspergillosis Patient Acquired or Environmental?Jochem B Buil, Jacques F Meis, Willem J G Melchers, et al.
Diagnostic Microbiology and Infectious Disease|September 23, 2011
In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility TestingShivaprakash M Rudramurthy, Arunaloke Chakrabarti, Erik Geertsen, et al.
Mycoses|April 27, 2011
In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugsM R Shivaprakash, Erik Geertsen, Arunaloke Chakrabarti, et al.
The Journal of Infection|December 3, 2014
Debridement, antibiotics and implant retention in early postoperative infection with Pseudomonas aeruginosaEwout S Veltman, Fidel J Vos, Jacques F Meis, et al.
Mycoses|July 31, 2018
Internal validation of GPS<sup>™</sup> MONODOSE CanAur dtec-qPCR kit following the UNE/EN ISO/IEC 17025:2005 for detection of the emerging yeast Candida aurisAntonio Martínez-Murcia, Aaron Navarro, Gema Bru, et al.
Pageof 43

Showing results (61-70 of 430) with videos related to

Sort By:
Pageof 43
Mycoses|December 11, 2019
Genotypic diversity in clinical and environmental isolates of Cryptococcus neoformans from India using multilocus microsatellite and multilocus sequence typingAnupam Prakash, Gandhi Sundar, Brijesh Sharma, et al.
Mycoses|February 11, 2021
COVID-19-associated pulmonary aspergillosis: a prospective single-center dual case seriesEelco F J Meijer, Anton S M Dofferhoff, Oscar Hoiting, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 10, 2021
Antifungal activity of nitroxoline against Candida auris isolatesFrieder Fuchs, Herbert Hof, Sandra Hofmann, et al.
Emerging Infectious Diseases|August 23, 2014
Passive surveillance for azole-resistant Aspergillus fumigatus, United States, 2011-2013Cau D Pham, Errol Reiss, Ferry Hagen, et al.
Mycoses|March 11, 2015
In vitro susceptibility patterns of clinically important Trichophyton and Epidermophyton species against nine antifungal drugsHamid Badali, Rasoul Mohammadi, Olga Mashedi, et al.
Antimicrobial Agents and Chemotherapy|April 24, 2016
Are the TR46/Y121F/T289A Mutations in Azole-Resistant Aspergillosis Patient Acquired or Environmental?Jochem B Buil, Jacques F Meis, Willem J G Melchers, et al.
Diagnostic Microbiology and Infectious Disease|September 23, 2011
In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility TestingShivaprakash M Rudramurthy, Arunaloke Chakrabarti, Erik Geertsen, et al.
Mycoses|April 27, 2011
In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugsM R Shivaprakash, Erik Geertsen, Arunaloke Chakrabarti, et al.
The Journal of Infection|December 3, 2014
Debridement, antibiotics and implant retention in early postoperative infection with Pseudomonas aeruginosaEwout S Veltman, Fidel J Vos, Jacques F Meis, et al.
Mycoses|July 31, 2018
Internal validation of GPS<sup>™</sup> MONODOSE CanAur dtec-qPCR kit following the UNE/EN ISO/IEC 17025:2005 for detection of the emerging yeast Candida aurisAntonio Martínez-Murcia, Aaron Navarro, Gema Bru, et al.
Pageof 43